Clinical Trial

Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-12-17; most recent amendment 2026-03-17.
Status change: Enrolling by Invitation → Recruiting 2026-03-17
Status change: Recruiting → Enrolling by Invitation 2023-08-28
Trial Details
NCT Number NCT05179889
Lead Sponsor Chungnam National University Hospital
Collaborators: Boryung Pharmaceutical Co., Ltd
Conditions Colon Cancer Stage III
Enrollment 308 participants
Start Date 2021-07-06
Primary Completion 2028-07-05 (estimated)
Study Completion 2031-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-19